Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other



SQZ Biotechnologies Co (SQZ) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Cost Associated with Exit or Disposal Activities, Material Impairments, Departure of Directors or Certain Officers; Election ...
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/25/2023 8-K Quarterly results
07/19/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
07/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/03/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events ...
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/22/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A 683 Capital Management, LLC reports a 4.5% stake in SQZ Biotechnologies Company
02/14/2023 SC 13G/A AMERICAN INTERNATIONAL GROUP, INC. reports a 8.5% stake in SQZ Biotechnologies Company
02/14/2023 SC 13G/A NanoDimension II Management Ltd reports a 4.9% stake in SQZ biotechnologies company
01/26/2023 4 Capasso Richard (See Remarks) has filed a Form 4 on SQZ Biotechnologies Co
Txns: Granted 213,000 options @ $0.73, valued at $155.5k
01/26/2023 4 Warren Marshelle Smith (Chief Medical Officer) has filed a Form 4 on SQZ Biotechnologies Co
Txns: Granted 261,000 options @ $0.73, valued at $190.5k
01/26/2023 4 Knopf Lawrence J (General Counsel) has filed a Form 4 on SQZ Biotechnologies Co
Txns: Granted 227,000 options @ $0.73, valued at $165.7k
01/26/2023 4 First David (Chief People Officer) has filed a Form 4 on SQZ Biotechnologies Co
Txns: Granted 200,000 options @ $0.73, valued at $146k
01/26/2023 4 BERNSTEIN HOWARD PHD MD (Interim Chief Executive Office) has filed a Form 4 on SQZ Biotechnologies Co
Txns: Granted 830,000 options @ $0.73, valued at $605.9k
01/18/2023 8-K Quarterly results
12/06/2022 8-K Quarterly results
11/30/2022 8-K Quarterly results
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/06/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SQZ Biotechnologies Announces Leadership Transition Chief Scientific Officer, Howard Bernstein, M.D., Ph.D., to Become Member of the Company’s Board of Directors, Effective October 31, 2022 CSO Responsibilities to be Shared Among Ipsita Roymoulik, Ph.D., Scott Loughhead, Ph.D., and Maisam Dadgar as Senior Leaders of Chemistry, Manufacturing and Controls; Translational Research; and Engineering WATERTOWN, Mass., September 6, 2022 –"
08/16/2022 4 Capasso Richard (See Remarks) has filed a Form 4 on SQZ Biotechnologies Co
Txns: Sold 1,183 shares @ $3.3262, valued at $3.9k
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/13/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/11/2022 8-K Quarterly results
07/05/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/05/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/05/2022 4 Capasso Richard (See Remarks) has filed a Form 4 on SQZ Biotechnologies Co
Txns: Granted 1,183 shares @ $2.703, valued at $3.2k
06/16/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/16/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/16/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy